Pfizer Inc. (NYSE:PFE) is among the 12 Best Ethical Companies to Invest in 2025. On July 24, 2025, Pfizer Inc. (NYSE:PFE) ...

As part of the agreement, which was signed in May 2025, 3SBio will receive $1.25bn, along with a $100m equity investment from ...

Pfizer agreed to an upfront payment of US$1.25 billion, US$150 million for mainland rights and a US$100 million equity ...

Moderna has scrapped plans to build an mRNA plant in Japan. Otsuka and Lundbeck's proposal for Rexulti as part of a PTSD ...

HONG KONG, Aug. 24, 2023 /PRNewswire/ -- Chinese leading biopharmaceutical company 3SBio (01530.HK) today released its 2023 interim results. Revenue in the first half of 2023 reached approximately ...

Pfizer’s stock climbed 2.4% in morning trading, while Merck shares gained 1.7%. As Cantor Fitzgerald analyst Carter Gould put it, Pfizer’s deal with 3SBio thrusts the company into the PD-1 ...

3SBio is a leading biopharmaceutical company in China. It is one of the earliest biologics innovators in the country, launching EPIAO in 1998 and TPIAO in 2005. The current portfolio is older ...

Narrow-moat 3SBio reported revenue and earnings that were in line with our expectations. Our fair value estimate is unchanged at HKD 11.70 per share. 3SBio’s pipeline is still early-stage, and ...

3SBio Inc. Annual stock financials by MarketWatch. View the latest 1530 financial statements, income statements and financial ratios.

3SBio Inc. Annual cash flow by MarketWatch. View 83B net cash flow, operating cash flow, operating expenses and cash dividends.

NEW YORK, Feb 6 (Reuters) - Chinese biotechnology firm 3SBio Inc. on Tuesday raised $123.2 million with an initial public offering that was priced above range. The 7.7 million American depositary ...

Chinese biotechnology firm 3SBio , which agreed to be taken private by a group that includes its Chief Executive Jing Lou, said the consortium raised its offer to $16.70 per American Depositary ...